PSY 433 Lecture Notes - Lecture 45: Cyp2D6, Psy, Atomoxetine
29 Jul 2020
Department
Course
Professor
Document Summary
Improvements have also been found in global functioning scales, in intra-family and social relations and improvement in depressive symptoms at doses of 1. 2 and 1. 8 mg/kg/day. In a subsequent study (kratochvil and cols, 2005) they evaluate both the safety of the atomoxetine/fluoxetine association in patients with adhd and depressive and anxious comority, and the response to placebo-associated atomoxetine treatment. This design was trying to see to what extent i"vebeen able to see that cytochrome p-450 2d6 involved in the metabolization of both drugs could influence the safety of the combination treatment. The improvement appeared within treatment week and was maintained throughout the study. The padres also reported improvements in overall functioning and depressive symptoms. Lately, the results of a meta-analysis, which includes six clinical trials, have been published,and n where it assesses results in adolescents (wilens et al. , 2006). The results conclude that atomoxetine is equally effective in children aged 6 to 11 as in adolescents aged 12-17 years.
